Korea Q1 Roundup: Pharma Begins To Feel Impact From Doctors’ Walkout

Mainstays Generally Strong

As South Korea's doctors continue their long-running protest against a government plan to raise the medical student quota at universities, the walk-outs may be beginning to take a toll on the pharma industry, with many large firms reporting weak earnings in the last quarter.

hospital chaos
Q1 Korean Pharma Earnings Sag Amid Disruptions At Hospitals • Source: Shutterstock

The South Korean pharma industry is beginning to feel the fallout from the prolonged national walkout by trainee doctors that began in February.

More from South Korea

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By 

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.

Korea Needs To Think Bigger On M&As: KHIDI

 

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.

Japan-Korea Venture Collab Grows With VC And Regulatory Meetups

 
• By 

Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band

 
• By 

The latest activity in the South Korean biotech sector includes IPOs by Orum and Dongkook Life, as well as progress with ADCs at multiple firms.

More from Focus On Asia